ERBB3 and breast carcinoma: In contrast, the Fab of trastuzumab was ineffective in blocking the association of HER2 with HER3 in human breast cancer cells expressing low or high levels of HER2 [26] and, therefore, ADCC is the major mechanism of action of trastuzumab.